How did OBIO's revenue and expenses trend in Q4 2024?

Orchestra BioMed (OBIO) experienced a revenue of $633,000 in Q4 2024, with total expenses amounting to $16.87 million, comprising $10.97 million in R&D expenses and $5.9 million in selling, general, and administrative (SG&A) expenses.

|code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code|
|---|---|---|---|---|---|---|
|OBIO|OBIO.O|Orchestra BioMed|20240101-2024|Product|633000|185|
|OBIO|OBIO.O|Orchestra BioMed|20240101-2024|Product|457000|185|
|OBIO|OBIO.O|Orchestra BioMed|20240101-2024|Product|273000|185|
|OBIO|OBIO.O|Orchestra BioMed|20240101-2024|Product|123000|185|
|OBIO|OBIO.O|Orchestra BioMed|20240101-2024|Partnership|497000|185|
|OBIO|OBIO.O|Orchestra BioMed|20240101-2024|Product|123000|185|

|code|Ticker|Name|Date|Selling, General, and Administrative Expenses|R&D Expenses|market_code|
|---|---|---|---|---|---|---|
|OBIO|OBIO.O|Orchestra BioMed|2024 Q1|5897000|9112000|185|
|OBIO|OBIO.O|Orchestra BioMed|2024 Q2|6467000|1.1126E7|185|
|OBIO|OBIO.O|Orchestra BioMed|2024 Q3|5666000|1.1595E7|185|
|OBIO|OBIO.O|Orchestra BioMed|2024 Q4|5901000|1.0971E7|185|